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25 ABSTRACT
26 Childhood acute lymphoblastic leukaemia (ALL) with MLL rearrangement (MLL-r) is 
27 an aggressive disease still associated with a high mortality rate.  Recent investigations 
28 have identified co-operating mutations in the RAS pathway and although the functional 
29 consequences of these mutations are not yet fully understood, aberrant regulation of 
30 RAS pathway signalling at both transcriptional and protein levels is observed.  Studies 
31 investigating the efficacy of specific inhibitors of this pathway, e.g. MEK-inhibitors, 
32 have also achieved encouraging results.  In this context, this mini-review summarizes 
33 the available data surrounding MLL-r infant ALL with RAS mutation in relation to other 
34 well-known features of this intriguing disease.
35
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44 1. Introduction
45 It is no longer a surprise when a new study reports that children with the most common 
46 type of childhood cancer, acute lymphoblastic leukaemia (ALL), have a survival rate of 
47 85% or more [1].  Indeed the survival rates have increased for girls and boys of varied 
48 ethnic groups and age groups except in infants (≤1 year-old).  Among these very young 
49 children, even those enrolled in the most recent and specific therapeutic protocols, only 
50 ~50% achieve long-term event-free survival (EFS) [2].  The main cause of this dismal 
51 outcome in infants with ALL (iALL) is the high prevalence of rearrangement of the 
52 mixed-lineage leukaemia gene (MLL, also known as KMT2A).  The presence or absence 
53 of an MLL rearrangement (MLL-r) is paramount both to provide a realistic prognosis 
54 and to determine a high-risk treatment strategy.  These features have been recognised 
55 for many years but, unfortunately, have not yet been converted into significantly better 
56 therapeutic strategies and improved outcomes.  Recent studies consistently show that 
57 KRAS and/or NRAS mutations (RASmut) are recurrent within patients with MLL-r, with 
58 MLL-AF4+ B-cell precursor ALL (BCP-ALL) being the most targeted subset.  This is 
59 of particular translational interest since the RAS signalling pathway offers an alternative 
60 therapeutic strategy for MLL-r ALL patients.
61
62 2. MLL-associated childhood acute lymphoblastic leukaemia
63 Childhood ALL characterized by MLL-r is a disease associated with aggressive clinical 
64 features.  It is remarkable that 80% of iALL cases harbour an MLL-r, whereas MLL-r is 
65 only occasionally observed in older children with ALL (~5%) [3-5].  The genetic lesion 
66 leads to an extremely aggressive subset of leukaemia, frequently associated with early 
67 age onset, high white blood cell count (WBC), hepatosplenomegaly and central nervous 
BBA Reviews on Cancer - Mini-Review
4
68 system (CNS) involvement.  While children diagnosed with other subtypes of 
69 leukaemia experience good prognosis (80-90% overall survival rates, OS), children with 
70 MLL-r present a high mortality rate (~50%) [2, 6].  Worldwide, this rare group of 
71 patients remains a major challenge for paediatric oncology.
72
73 2.1.  A spectrum of MLL rearrangements in childhood acute lymphoblastic leukaemia
74 Chromosomal abnormalities involving the MLL gene are very heterogeneous including 
75 reciprocal translocations, complex rearrangements, internal duplications, inversions and 
76 deletions, among others.  The majority of the rearrangements are cytogenetically 
77 unbalanced [7, 8].  To date, more than 80 different direct MLL-r and about 120 
78 reciprocal MLL-r have been reported and characterized at the molecular level [8].  
79 Despite this broad cytogenetic spectrum, the most frequent partners in childhood ALL 
80 are limited to three: AF4/AFF1, AF9/MLLT3 and ENL/MLLT1, with the MLL-AF4 
81 fusion being associated with a very early age at diagnosis, pro-B ALL phenotype and 
82 very poor outcome.
83 The distribution of chromosomal breakpoints has also been the subject of 
84 investigation.  The breakpoint cluster region located between MLL exon 9 and intron 11 
85 is responsible for 93.5% of breaks.  The localization of breakpoints varies according to 
86 age, type of leukaemia and MLL partner gene [9], indicating that the underlying 
87 molecular mechanisms that drive the rearrangements are also different.  Of note, we 
88 previously showed that the OS of children with breakpoints in MLL intron 11 was worse 
89 compared to other locations [6].
90
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91 2.2.  The lack of multiple genetic abnormalities in MLL-r ALL
92 Studies evaluating iALL have demonstrated that twin pairs with a monochorionic 
93 placenta and concordant leukaemia share identical genomic MLL-r [10, 11].  In non-
94 twined siblings, the genomic breakpoint sequence is detectable in neonatal blood spots 
95 [12].  Collectively, these findings provide strong evidence for an in utero origin of this 
96 disease and also, given the short latency period, suggest that MLL-r may be the only 
97 required genetic hit necessary to induce overt leukaemia or that very few additional 
98 mutations are required.  In agreement, data obtained from genome-wide studies has 
99 consistently shown that secondary genetic alterations are rarely found in MLL-r ALL 
100 [13-15].  More recently, this deficit of additional mutations, when compared to other 
101 types of human cancer, led to the conclusion that iALL with MLL-r display one of the 
102 lowest somatic mutation rates [7].  This frank discovery supports the repeated assertion 
103 that this single genetic lesion is sufficient for malignant transformation [16, 17].
104
105 3. A renaissance for RAS mutation investigation in MLL-r leukaemia
106 The genes that encode RAS proteins have been recognised as powerful drivers of cancer 
107 for more than three decades.  The first screening of RASmut in MLL-r ALL samples 
108 dates from 1998, when Mahgoub and colleagues hypothesized that this pathway might 
109 play a role in this leukaemia subtype.  Despite an analysis of 13 samples, RASmut were 
110 absent in that series [18].  The debate remained subdued in the literature until 2006, 
111 when Liang et al. reported that 10 of 20 MLL-r ALL samples harboured a RASmut [19].
112 Despite the very low frequencies of copy number abnormalities in MLL-r 
113 leukaemia observed through genome-wide analysis [13, 15], consecutive experimental 
114 models showed that MLL fusion proteins synergistically cooperate with activation of 
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115 RAS in leukaemogenesis [20-22].  These data helped renew the search to determine the 
116 frequency of RASmut in MLL-r ALL.  Driessen et al. screened 109 iALL samples for 
117 NRAS and KRAS and found that the mutations were significantly more frequent (23.7% 
118 versus 7.8%) in infants with MLL-AF4 [23].  Similarly, Prelle and colleagues 
119 investigated 80 paediatric leukaemia samples and observed similar results, finding 
120 RASmut in 26% of MLL-AF4 cases and in 10% of patients with other MLL-r [24].  In 
121 conjunction these studies led to important conclusions regarding frequency of RASmut 
122 in MLL-r ALL: that they are recurrent and the mutations are especially associated with 
123 the MLL-AF4 subset.
124
125 3.1.  Frequencies of RAS mutations obtained through next-generation sequencing
126 The aforementioned studies used conventional Sanger sequencing to determine the 
127 frequency of RASmut in MLL-r leukaemia.  The advent of next generation sequencing 
128 (NGS) technologies has allowed the delivery of massive and accurate genome 
129 information [25].  Taking advantage of such revolutionary technology, Andersson et al. 
130 performed a detailed paired-end genome-wide analysis on diagnostic and matched 
131 remission samples of 22 iALL with MLL-r.  They observed that 100% of the mutant 
132 alleles in tyrosine kinase-phosphoinositide 3-kinase (PI3K)-RAS pathways were 
133 expressed.  The authors confirmed the data in a validation cohort to show that 16 of 47 
134 (34%) infant MLL-r cases and 11 of 23 (48%) cases positive for MLL-AF4 harboured an 
135 activating mutation in RAS pathway genes [7].
136 In 2016, Trentin and colleagues also used NGS technology to screen RASmut in 
137 MLL-AF4 positive paediatric and iALL patients, the most frequently targeted subgroup.  
138 Using ultra deep sequencing, they described RASmut in 63.9% diagnostic samples of 
BBA Reviews on Cancer - Mini-Review
7
139 patients with MLL-AF4 positive ALL [26].  To date, this is the highest reported 
140 frequency of RASmut in MLL-r cases, and this result is fully explained by the sample 
141 cohort (restricted to MLL-AF4 subgroup) as well as the sensitivity of the sequencing 
142 method applied.  Nevertheless, 36 out of 49 reported mutations (73.5%) were present in 
143 minor clones (mutant allele frequency, MAF < 10%).
144 In summary, the frequency of RASmut in infants and children with MLL-r BCP-
145 ALL varies from 25-60% of cases, depending on selection criteria and sequencing 
146 method applied.  A consensual assumption is that this prevalence is markedly increased 
147 in patients with the MLL-AF4 fusion (Figure 1).  Despite these differences, the striking 
148 conclusion is that this pathway is indeed an important target of disruption in patients 
149 with MLL-r ALL.
150
151
152 Figure 1. Frequency of KRAS/NRAS mutations in cases with any MLL-rearrangement or 
153 cases with the specific MLL-AF4 gene fusion.  The frequencies are shown according to the 
154 screening method.  When analysed by Sanger sequencing, RAS mutations are expected in 10% 
155 or 25% of cases with MLL-r or MLL-AF4, respectively.  Using next generation sequencing, RAS 
156 mutations are expected in 35% or 50% of cases with MLL-r or MLL-AF4, respectively.
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157
158 3.2.  The subclonality of RAS mutations
159 Although using different design strategies, the studies that addressed the question 
160 whether RASmut in MLL-r ALL were either clonal or subclonal arrived at the same 
161 conclusion: the mutations are present in minor clones at diagnosis.  Driessen et al. 
162 sequenced PCR-amplified DNA fragments cloned from three patient samples and found 
163 that in all of them the percentage of mutated fragments was lower than 50%, suggesting 
164 the subclonal nature of the mutations [23].  Using pyrosequencing, a quantitative 
165 sequencing method, we observed that in 19 out of 20 MLL-r iALL cases the percentage 
166 of RASmut alleles at diagnosis was lower than expected for a clonal alteration [27].  In 
167 concordance, the observation that 65% of the activating tyrosine kinase-PI3K-RAS 
168 mutations found in 22 MLL-r cases had MAFs <30% led Andersson et al. to conclude 
169 that these mutations were present in minor clones.  The authors also suggested that an 
170 activating mutation in RAS signalling pathways is not crucial for the establishment of 
171 the leukaemia, but rather contributes to growth advantage.  Of note, regardless of the 
172 MAFs, all cases that were also analysed by RNA-seq expressed the activating mutant 
173 allele [7].
174 Irrefutable data about clonality came from studies that evaluated matched 
175 diagnosis and relapse samples and revealed a highly heterogeneous pattern of clonal 
176 evolution, with some cases showing the same RAS mutation at diagnosis and relapse 
177 and other cases showing gain or loss of RAS mutations at relapse [7, 26, 28, 29].  This 
178 profile supports the subclonal nature of RAS mutations and suggests that the treatment 
179 pressure can either positively or negatively select the RAS mutated clone at relapse.
180
181 3.3.  Contribution of RAS mutations to MLL-driven leukaemogenesis
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182 Although the functional consequences of RAS mutations in MLL-r patients, especially 
183 those only present in minor clones, are not yet fully understood, functional studies have 
184 been conducted in the past few years that attempt to evaluate the role played by RASmut 
185 in MLL-driven leukaemias.  It has been shown that these mutations result in over 
186 expression of RAS pathway signalling at both transcriptional and protein levels and that 
187 a potential collaboration between those two abnormalities may strongly contribute to the 
188 leukaemogenic process.
189 In that context, the transcription of Elk-1, a major effector of Ras signalling, was 
190 activated by the MLL-AF4 family fusion oncoproteins: MLL-AF4, MLL-LAF4 and 
191 MLL-AF5q31.  Interestingly, when either the MEK-inhibitor U0126 or a dominant 
192 negative mutant of Ras (HRas S17N) were used, this transcriptional activation was 
193 abrogated.  This data strongly links activation of Ras signalling to MLL-r 
194 leukaemogenesis [20].
195 Another investigation using a xenograft model with MLL-fusion mediated 
196 leukaemogenesis evaluated the cooperation between MLL-fusions (MLL-SEPT6 and 
197 MLL-ENL) and RAS mutations (NRAS G12V).  In summary, the authors suggested that 
198 the crosstalk between MLL-r and RASmut may occur, at least partially, due to the 
199 aberrant expression of Hoxa9, a critical and direct MLL transcriptional target [21].
200 Similarly, by developing an oncogenic aggressive murine model, Tamai et al. 
201 were able to generate an MLL-AF4+ KRas G12D transgenic mouse that developed B-
202 cell lymphoma and/or leukaemia in a 6-month latency period that resembled MLL-r 
203 leukaemia in humans.  Corroborating the study outlined above, leukaemogenesis was 
204 most likely accelerated by Hoxa9 overexpression, as a result of MLL-AF4 and KRasmut 
205 cooperation [22].
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206 More recently, it was observed that KRAS G12V either alone or combined with 
207 MLL-AF4 was unable to initiate leukaemia, however did enhance haematopoietic 
208 engraftment in immunodeficient mice and increased significantly the ability of cord 
209 blood-derived cells to infiltrate the CNS, both hallmarks of MLL-AF4+ BCP-ALL.  
210 Altogether, their results indicate that KRAS plays an important role in MLL-AF4-driven 
211 leukaemias maintenance, but not in disease initiation [30].
212
213 3.4.  Prognostic value of RAS mutations in patients with MLL-r ALL
214 The occurrence of MLL-r is the strongest prognostic marker to independently predict 
215 dismal outcome in iALL, the EFS rate in this leukaemia subgroup being considerably 
216 poor, ~28-36% [2].  Besides MLL-r, other molecular markers, such as RASmut, have 
217 been selected as prognostic predictors in infants.
218 In 2013, Driessen and colleagues showed that RASmut iALL cases exhibit a high 
219 WBC at diagnosis and glucocorticoid resistance in vitro, two factors linked to disease 
220 aggressiveness.  Moreover, in terms of 5-year OS and EFS, the presence of RASmut was 
221 independently associated with dismal prognosis [23].  A year later, our own group 
222 published data ratifying the prognostic value of RASmut in a Brazilian iALL series of 
223 cases.  Although not independently, the presence of RASmut was a predictor of adverse 
224 outcome.  Moreover RASmut was also found to be associated with the occurrence of 
225 MLL-AF4 translocation (OR 5.78; 95% CI 1.00 – 33.24) in those cases [31].
226 Another study defining the genomic landscape of iALL with MLL-r, observed a 
227 trend toward poorer OS and EFS in patients carrying RASmut, however in contrast to 
228 previous investigations, they found no statistical significance for this data. [7].  One 
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229 potential critique is the number of patients included in the survival analyses, only 33 
230 and 31 cases were evaluated for 10-year OS and EFS, respectively.  Even so, it is 
231 important to highlight that other studies also with small cohorts were still able to 
232 observe statistically significant results on their survival analyses.
233 The role of RAS mutations on MLL-r patients prognosis has also been recently 
234 evaluated by Trentin et al., who showed that, in agreement with previous reports, 
235 patients harbouring RAS mutations had worse outcomes than those with RAS wild-type 
236 [26].  Similar to the study mentioned above, the number of infant patients included was 
237 fairly small (n=22) and no significance was found.
238
239 4. Other high-risk groups with RAS mutations (hypodiploid ALL, iAMP21, T-
240 ALL)
241 In addition to MLL-r iALL, there are other high-risk groups of ALL in which RASmut 
242 are recurrently found and we discuss here three entities: hypodiploid ALL, 
243 intrachromosomal amplification of chromosome 21 (iAMP21) and T-cell acute 
244 lymphoblastic leukaemia (T-ALL).
245 By definition, hypodiploid ALL have fewer than 44 chromosomes and can be 
246 subdivided into three categories according to the number of chromosomes present: near-
247 haploid (24–31 chromosomes), low-hypodiploid (32–39) and high-hypodiploid cases 
248 (40–43 chromosomes).  Patients exhibiting 44-45 chromosomes are classified as near-
249 diploid and, unlike the other categories of hypodiploid ALL, do not present a poor 
250 prognosis.  Overall, the genetic profile of hypodiploid ALL is still poorly defined, but it 
251 is well recognised that this leukaemic subtype is characterised by whole-chromosomal 
252 losses and extremely sombre outcomes [32].  Considering the paucity of studies 
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253 evaluating the genetic basis of hypodiploid ALL, Holmfeldt et al. delineate the genomic 
254 landscape of 124 paediatric patients diagnosed with this high-risk subtype.  By using 
255 next generation sequencing, they described activation of both RAS- and PI3K-signalling 
256 pathways as the main molecular events in these cases.  Particularly regarding near-
257 haploid and low-hypodiploid subgroups, they showed a considerable recurrence of 
258 KRAS and NRAS abnormalities (copy number alterations and mutations) in 17.6% of the 
259 hypodiploid cases, with NRAS being the most affected gene.  As expected, mutations 
260 were found mainly in codons 12 and 13 of both RAS genes.  Evaluating the impact of 
261 those RAS abnormalities on patient survival, no significant differences were observed 
262 when comparing patients with and without mutations [33].
263 iAMP21 accounts for 2% of paediatric ALL and was identified more recently as 
264 a distinct cytogenetic subgroup characterised by the presence of additional copies of 
265 RUNX1.  In fact, the international classification of iAMP21 is accepted as the presence 
266 of 3 or more extra copies of RUNX1 on a single abnormal chromosome 21, i.e. 5 or 
267 more RUNX1 signals per cell.  Patients with iAMP21 have a very dismal outcome when 
268 treated with standard therapy and the relapse rate is very high.  Recently however, 
269 protocols such as the United Kingdom acute lymphoblastic leukaemia protocol 
270 (UKALL), has been treating those patients in the more intensive/high-risk treatment 
271 arm (in spite of other risk factors) and the initial results seem very promising [34].  The 
272 mutational landscape of the RAS pathway was also recently investigated in a series of 
273 44 diagnostic samples of iAMP21 ALL.  The study revealed a very high frequency 
274 (60%) of RAS pathway abnormalities (mutations involved NRAS, KRAS, FLT3, 
275 PTPN11, BRAF and NF1).  Moreover these mutations were genetically heterogeneous 
276 and resulted in some clonal heterogeneity, with mutations co-existing within a gene or 
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277 individual patient sample in different patterns.  Unfortunately, the prognostic impact of 
278 those RAS mutations was not evaluated in these series of iAMP21 cases [35].
279 T-ALL is an aggressive haematological malignancy characterised by high WBC 
280 count, presence of mediastinal mass, CNS involvement, ~20% relapse rate and older 
281 age for the paediatric group.  A significant number of cases fall into the high-risk group 
282 [36, 37].  In terms of genomic profile, NOTCH1 mutations and CDKN2A/B deletions 
283 are the main abnormalities affecting more than 50% of the T-ALL cases.  In light of 
284 currently available genomic data, it is possible to estimate that for each T-ALL case ~10 
285 genomic abnormalities are present, however the contribution and the role of all these 
286 lesions for the pathogenesis and prognosis of T-ALL is not yet fully understood [38].  
287 The occurrence of RAS mutations in T-ALL has been reported in the literature for the 
288 last few decades [39], especially in the early T-cell precursor ALL (ETP-ALL) 
289 subgroup [40].  However, in the past, most studies were experimental and used murine 
290 models to investigate the role of RAS mutations in leukaemogenesis [41].  More 
291 recently, Oshima et al. aiming to identify the mutational landscape of relapsed ALL 
292 observed a high frequency of RAS pathway (NRAS, KRAS and PTPN11) mutations 
293 (44%).  Particularly for the T-ALL cases they found 12% of KRAS mutations and 27% 
294 of NRAS in those relapse samples.  They also revealed that ALL relapse emerges from 
295 subclonal populations sharing only part of the mutations present in the dominant 
296 leukaemic clone found at diagnosis [29].  A recent study attempting to identify genes 
297 that could predict the ultra-high-risk group of relapse T-ALL, showed that RAS 
298 mutations were significantly enriched in this subgroup.  Moreover, all relapsed patients 
299 with RASmut evolved to death, resulting in a significantly worse EFS in this particular 
300 subgroup (p=0.0059) [42].
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301 In summary, a variety of studies investigating different high-risk ALL subgroups 
302 showed that mutations affecting the RAS pathway are major genetic events present in a 
303 significant fraction of high-risk cases.  Despite the fact that some studies, including our 
304 own in paediatric T-ALL [39], failed to show RASmut either as an independent 
305 prognostic factor or as OS and EFS statistically significant results, we should not rule 
306 out the importance of these RAS mutations in the leukaemogenesis of these aggressive 
307 subsets of ALL.
308
309 5. New therapeutic strategies using targeted therapy
310 Treating aggressive leukaemias classified as high-risk cases, such as MLL-r iALL, 
311 remains a major challenge in paediatric haematology worldwide, therefore the 
312 development of new therapeutic strategies is imperative.  In this regard, many 
313 international collaborative efforts have been initiated and are currently in progress 
314 through the use of novel targeted therapies based on iALL molecular biology.
315 Particularly for MLL-r iALL, currently there are four main lines of new targeted 
316 therapy under investigation: Clofarabine, FLT3-inhibitors, epigenetic modifiers and 
317 MEK-inhibitors.  Clofarabine is a nucleoside analogue and, since infant leukaemic cells 
318 are known to be sensitive to this class of drug, its implementation in the current 
319 leukaemia protocols might prove to be beneficial in the treatment of those high-risk 
320 patients.  FLT3-inhibitors, such as Lestaurtinib (CEP-701), Midostaurin (PKC412) and 
321 Quizartinib (AC220), act against the high-levels of FLT3 expression.  The inclusion of 
322 these inhibitors in the clinic could potentially benefit 80% of MLL-r iALL cases, since 
323 this is the frequency of patients that exhibit FLT3 overexpression.  Epigenetic modifiers 
324 seem to be the most appealing class of drugs to treat MLL-r iALL, since this leukaemia 
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325 subtype is characterised by globally aberrant methylation profiles.  These modifiers can 
326 be subdivided into 4 classes: demethylating agents (Azacitidine, Decitabine), histone 
327 deacetylase inhibitors (Vorinostat, Panobinostat), DOT1L-inhibitor (EPZ-5676) and 
328 BET protein inhibitors (OTX-015).  A promising international collaborative trial for 
329 iALL involving the use of epigenetic modifiers is underway and will involve the 
330 Interfant, COG, and JPLSG groups [43].
331 MEK-inhibitors are also a new class of drugs that have great potential to be used 
332 in combined therapy approaches in MLL-r iALL patients that harbour RAS pathway 
333 abnormalities (Figure 2).  Currently the following MEK-inhibitors are being tested in 
334 advanced stages of clinical trial: Trametinib (GSK1120212), Pimasertib 
335 (MSC1936369B) and Selumetinib (AZD6244, ARRY-142886).  In theory these types 
336 of inhibitor should result in less “off target” activity, inhibiting the pathway despite the 
337 mechanism of upstream activation.  Data coming from in vitro and in vivo models of 
338 both FLT3-mutant and RAS-mutant acute leukaemias have shown very encouraging 
339 results [44, 45].  In 2016, Kerstjens et al. investigated the effects of MEK-inhibitors in 
340 MLL-r iALL cells carrying RAS mutations.  They showed that after treatment with 
341 Trametinib, Selumetinib and MEK162 those cells exhibited an increased apoptosis and 
342 enhanced prednisolone sensitivity.  At first, one may argue that considering the 
343 subclonal nature of RASmut, targeting of minor clones could be a questionable 
344 approach.  However, they have also observed that the use of MEK inhibitor enhances 
345 overall sensitivity to prednisolone treatment of both RAS wild-type and RASmut MLL-r 
346 ALL cells [46].  Additionally, three other studies have observed the same sensitizing 
347 effect of MEK inhibitors in the response to glucocorticoids (methylprednisolone, 
348 prednisolone and dexamethasone) [47-49].
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350 Figure 2.  Schematic representation of RAS signalling pathway showing the use of MEK-
351 inhibitors.  The occurrence of RAS mutations results in abnormal activation of RAS pathway 
352 proteins, such as MEK1/2, which can be targeted by specific inhibitors (Trametinib, Pimasertib 
353 and Selumetinib).
354
355 6. Closing remarks
356 Infant ALL is a rare entity but the aggressive nature and high mortality rate of the 
357 disease, especially for those cases with MLL-r, challenge both researchers and clinicians 
358 to unravel its complex molecular biology.  RAS mutations in infants and children with 
359 MLL-r BCP-ALL play an important role in the maintenance of disease and despite 
360 intensive current treatment regimens the majority of patients with iALL still relapse and 
361 die.
362 The latest international and collaborative studies investigating the efficacy of 
363 specific inhibitors of the RAS pathway are already producing encouraging results.  We 
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364 hope that in the near future these combined therapeutic approaches will act 
365 synergistically both to increase survival rates and reduce treatment-related toxicities.
366
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